Inagene Launches GLP-1 Insights Program for Personalized Medication Support

TORONTO, Sept. 24, 2026 /CourierPR/ -- Inagene Diagnostics, a Canadian company headquartered in Toronto, Ontario, has launched a new product called the GLP-1 Insights Program. This program aims to provide personalized genetic insights into GLP-1 medications, along with support from registered dietitians to help Canadians understand their genetic response to weight management and diabetes medications. The program is designed to address the wide variability in individual responses to GLP-1 medications and the high rate of discontinuation due to side effects.

Approximately 3 million adults in Canada currently take a GLP-1 medication, while more than 2 million are estimated to be interested in pursuing treatment. However, most people who start taking GLP-1 medications are estimated to be off them within a year, with side effects reported as a major barrier.

The GLP-1 Insights Program combines a simple thirty-second at-home cheek swab with three personalized sessions with a registered dietitian. The program provides easy-to-understand insights into how an individual’s genetics may influence their response to certain medications. New research has linked certain genetic variants to improved response to semaglutide (Ozempic, Wegovy) and tirzepatide (Mounjaro, Zepbound), as well as differences in the likelihood of experiencing side effects such as severe nausea or vomiting. The Inagene GLP-1 Insights Program also reports variants that research has associated with differences in response to certain diabetes medications.

Alongside genetic insights, the program includes three sessions with a registered dietitian to provide personalized support to help individuals make sustainable dietary changes and feel more confident as they adapt to their treatment. The goal is to give people information they can bring to the conversation with their healthcare provider.

Research suggests that approximately 3 million adults in Canada currently take a GLP-1 medication, while more than 2 million are estimated to be interested in pursuing treatment. Most people who start taking GLP-1 medications are estimated to be off them within a year, with side effects reported as a major barrier. According to the OMNI Report, published on March 3, 2026, GLP-1 usage in Canada and the US has seen significant growth. The JAMA Network Open, published on January 2, 2025, reported that discontinuation and reinitiation of dual-labeled GLP-1 receptor agonists among US adults with overweight or obesity are common. Additionally, the National Institutes of Health (NIH) reported that causes and consequences of discontinuation of GLP1RAs or tirzepatide are complex and multifaceted.